可调控危险因素与心房颤动
本文综述了可调控危险因素在心房颤动(AF)发病中的作用及危险因素管理的获益证据。AF负担持续上升,导管消融成功率未显著提升,生活方式与危险因素管理作为上游无创治疗有望减少AF发生与进展,文章提出将危险因素干预作为AF综合管理的第四支柱。
要点
- 可调控危险因素参与AF发病,上游干预有望减少AF发生与进展。
- 导管消融技术进步未显著提高手术成功率,需加强危险因素管理。
- 建议将危险因素干预纳入AF综合管理,与率控制、节律控制、抗凝并列。
核心结论
- 危险因素管理可作为AF上游无创治疗,减少AF发生与进展,并应纳入综合管理。
研究设计与样本
- 综述,整合基础与临床研究证据,讨论危险因素在AF发病中的作用及干预获益。
主要发现
- AF负担持续上升,现有治疗手段存在不足,导管消融成功率近年未显著提升。
- 生活方式与危险因素管理对AF具有潜在获益,支持其作为上游无创治疗。
临床怎么用
- 在AF常规管理基础上,将危险因素干预作为综合管理的一部分,与率控制、节律控制、抗凝并列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There has been increasing focus on the rising burden of atrial fibrillation (AF) since the turn of the millennium. The AF epidemic is projected not only to have an impact on morbidity and mortality, but also to result in increasing healthcare use and cost. Intensive research over the previous decades has improved our understanding of this complex arrhythmia while unraveling more knowledge gaps and inadequacies of current therapeutic options. Specifically, the advances in catheter ablation technology and strategies have not translated into significant gains in procedural success rates over recent years. Therefore, strategies aiming at lowering the risk of AF development and progression are urgently needed to curtail the AF epidemic and improve outcomes in affected individuals. Recent research has highlighted the potential beneficial effects of lifestyle and risk factor management for AF as upstream noninvasive therapy. The evidence supporting this treatment paradigm beyond routine clinical AF management argues for change in the delivery of care to patients who have this debilitating arrhythmia. In this review, we highlight the contributory role of risk factors to AF pathogenesis from both bench and bedside studies. Next, we discuss the rationale and potential benefits of risk factor modification for sinus rhythm maintenance. Last, we propose an integrated care model to incorporate risk factor modification as the fourth pillar of AF care in conjunction with established pillars of rate control, rhythm control, and anticoagulation therapy.
引用
- Lau DH, Nattel S, Kalman JM, et al. Modifiable Risk Factors and Atrial Fibrillation. Circulation. 2017. PMID: 28784826. doi:10.1161/CIRCULATIONAHA.116.023163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。